New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

PRESS RELEASE Research Findings

19/10/2021

Merck

Merck, a leading science and technology company, today shared data in an oral presentation from a Phase II post-hoc analysis, demonstrating that the oral, central nervous system (CNS)-penetrant, fully covalent Bruton’s tyrosine kinase inhibitor (BTKi) evobrutinib impacted brain lesions associated with chronic inflammation in the CNS, making it the first BTKi to show significant reductions in slowly expanding lesions (SEL). SELs are chronic, active, demyelinated multiple sclerosis (MS) lesions, which are thought to be an early indicator of disease progression in MS. These data were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) days after the completion of enrolment into the Phase III EVOLUTION RMS program, in which evobrutinib is being investigated, was announced.

Related News

New Real-World MAVENCLAD® Data Show Sustained Effectiveness and Benefit on Quality-of-Life Measures in RMS Patients

Merck today announced new interim real-world data on MAVENCLAD® (cladribine tablets) that show patients with relapsing multiple sclerosis (RMS) experi...

19/10/2021

PRESS RELEASE

Merck Completes Enrolment of Evobrutinib Phase III Clinical Trials Ahead of ECTRIMS 2021

Merck today announced enrolment has been completed in the Phase III EVOLUTION RMS clinical trial programme, which is evaluating the efficacy and safet...

12/10/2021

PRESS RELEASE Corporate Announcements

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us